StockIQ.techAjinomoto Co., Inc. (2802.T) Stock Analysis
Free AI-powered analysis and research for Ajinomoto Co., Inc. stock
Sector: Consumer Defensive
2802.T snapshot
Data as of 16 Oct 2026 close. Updated daily.
Ajinomoto Co., Inc. scores 61/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 65% of its 52-week range, up 26.7% over the past year. Latest reported figures show a profit margin of 8.5%, return on equity of 18.5% and revenue growth of +13.2%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +2
- MACD Bullish: +8
- High P/E (36.8): -10
- Weak Liquidity (1.45 Current Ratio): -5
- Strong ROE (18.5%): +5
- High P/B (6.52): -5
- Above MA200: +4
- Healthy Momentum (+26.7% over 1 year): +7
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 2802.T report
Ajinomoto Co., Inc. (2802.T) is listed in the Consumer Defensive sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 2802.T Now →📰 Latest Update
Recombinant Proteins Market Forecasts Growth from $5.78B (2026) to $11.42B by 2032, Profiling GenScript, Takara Bio, Ajinomoto & 37 Other Key Players
Tue, September 15, 2026 at 2:46 PM UTC 2 min read
The recombinant proteins market is projected to grow from $5.78 billion in 2026 to $11.42 billion by 2032, highlighting significant opportunities for companies like GenScript, Takara Bio, and Ajinomoto. This growth indicates a robust demand for biopharmaceuticals and research tools, which could positively impact the financial performance of firms involved in this sector. Investors should consider the potential for increased revenue and market share among key players in the recombinant proteins space.